Delcath Systems Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 12, 2022 / 12:30PM GMT
Unidentified Participant

Good day, and thanks for joining us to have a conversation with Gerard Michel, CEO of Delcath. Delcath is an interventional oncology company that's developing in minimally invasive percutaneous perfusion technology to treat primary and secondary tumors of the liver. The company, under Gerard, has completed analysis of the Phase 3 study and is expected to file the NDA in the fourth quarter and recently have started commercializing the product in EU with its own sales force.

So to talk about the company's strategy for '22 and beyond, I welcome Gerard to this fireside chat with me. Gerard, glad to see you.

Gerard Michel - Delcath Systems, Inc. - CEO & Director

RK, (inaudible) Thank you for having me.

Unidentified Participant

And appreciate you accepting our invitation to join us. So Gerard, just to set up the stage for the audience here and help us familiarize with Delcath's business strategy, if you can start.

Gerard Michel - Delcath Systems, Inc. - CEO & Director<

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot